AcQMap Objectively Visualize the Etiology of Recurrent AF Following a Failed AF Ablation

NCT ID: NCT03368781

Last Updated: 2022-07-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-12

Study Completion Date

2020-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the AcQMap High Resolution Imaging and Mapping System during an atrial fibrillation retreatment ablation procedure. (CLP-AF-004 \[EU\])

A prospective, single-arm, multi-center, non-randomized, pre-market study designed to provide clinical data regarding the use of the AcQMap High Resolution Imaging and Mapping System during an atrial fibrillation retreatment ablation procedure. (CLP-AF-005 \[Canada\])

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, single-arm, multi-center, multi-national, non-randomized, post-market study designed to provide clinical data regarding the use of the AcQMap High Resolution Imaging and Mapping System during an atrial fibrillation retreatment ablation procedure. The patient population includes men and women, eighteen (18) years of age or older. The treatment plan must include evaluation and ablation (as indicated) of pulmonary vein reconnections plus AcQMap guided non-PV substrate ablation. Subject assessments will occur at screening, procedure, hospital discharge, 3-, 6-, and 12-months. (CLP-AF-004 \[EU\])

A prospective, single-arm, multi-center, multi-national, non-randomized, pre-market study designed to provide clinical data regarding the use of the AcQMap High Resolution Imaging and Mapping System during an atrial fibrillation retreatment ablation procedure. The patient population includes men and women, eighteen (18) years of age or older. The treatment plan must include evaluation and ablation (as indicated) of pulmonary vein reconnections plus AcQMap guided non-PV substrate ablation. Subject assessments will occur at screening, procedure, hospital discharge, 3-, 6-, and 12-months. (CLP-AF-005 \[Canada\])

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

None randomized, single-arm, open label.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AcQMap Imaging and Mapping

Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.

Group Type EXPERIMENTAL

AcQMap Imaging and Mapping System

Intervention Type DEVICE

3D Cardiac Imaging and Mapping during ablation procedures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AcQMap Imaging and Mapping System

3D Cardiac Imaging and Mapping during ablation procedures

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AcQMap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female eighteen (18) years of age or older
* Currently scheduled for a repeat endocardial ablation of AF where the index atrial fibrillation ablation procedure was completed ≤ twenty-four (24) months prior to enrollment and the subject has demonstrated at least one episode of post-ablation non-self-terminating AF

Exclusion Criteria

* No more than two (2) previous left-atrial ablations
* Structural heart disease or implanted cardiac devices
* History of blood clotting or bleeding disease
* Pregnant or lactating (current or anticipated during study follow up)
* Evidence of left atrial thrombus
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acutus Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Grace, MD

Role: PRINCIPAL_INVESTIGATOR

Papworth Hospital NHS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Brussel Centrum voor Hart-en Vaatziekten

Belsele, Jette, Belgium

Site Status

Southlake Regional Health Center

Newmarket, Ontario, Canada

Site Status

Na Homolce Hospital

Prague, , Czechia

Site Status

Klinikum Coburg

Coburg, , Germany

Site Status

Klinikum Coburg

Coburg, , Germany

Site Status

Herzzentrum der Universität zu Köln

Cologne, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

St. Antonius Hospital

Nieuwegein, , Netherlands

Site Status

Erasmus MC

Rotterdam, , Netherlands

Site Status

Papworth Hospital NHS

Cambridge, , United Kingdom

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

James Cook University Hospital

Middlesbrough, , United Kingdom

Site Status

Freeman Hospital

Newcastle, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Sheffield Teaching Hospital Northern

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada Czechia Germany Netherlands United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLP-AF-005

Identifier Type: OTHER

Identifier Source: secondary_id

CLP-AF-004-NL

Identifier Type: OTHER

Identifier Source: secondary_id

CLP-AF-004

Identifier Type: -

Identifier Source: org_study_id

NCT03467126

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Noninvasive Mapping Before Surgical Ablation
NCT06803615 ACTIVE_NOT_RECRUITING
AcQForce Pulsed Field Ablation-CE
NCT05113056 COMPLETED NA